BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9245869)

  • 1. Follow-up requirements for thick cutaneous melanoma.
    Sylaidis P; Gordon D; Rigby H; Kenealy J
    Br J Plast Surg; 1997 Jul; 50(5):349-53. PubMed ID: 9245869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrence of thin melanoma: how effective is follow-up?
    Moloney DM; Gordon DJ; Briggs JC; Rigby HS
    Br J Plast Surg; 1996 Sep; 49(6):409-13. PubMed ID: 8881790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma.
    Poo-Hwu WJ; Ariyan S; Lamb L; Papac R; Zelterman D; Hu GL; Brown J; Fischer D; Bolognia J; Buzaid AC
    Cancer; 1999 Dec; 86(11):2252-8. PubMed ID: 10590365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Melanoma in HIV patients: 14 cases].
    Qasmi S; Sutra-Loubet C; Maubec E; Boitier F; Duvillard P; Carlotti A; Marinho E; Jacobelli S; Franck N; Gorin I; Vacher-Lavenu MC; Bouscarat F; Crickx B; Dupin N; Avril MF
    Ann Dermatol Venereol; 2010 Dec; 137(12):769-74. PubMed ID: 21134578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational follow-up recommendations for patients with melanoma.
    Chartier T; Bigby M
    Arch Dermatol; 2000 Sep; 136(9):1145-7. PubMed ID: 10987873
    [No Abstract]   [Full Text] [Related]  

  • 6. Recurrence of cutaneous malignant melanoma after more than 20 years.
    Bredgaard R; Lock-Andersen J
    J Plast Surg Hand Surg; 2011 Apr; 45(2):113-6. PubMed ID: 21504283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evidence base for reconsidering current follow-up guidelines for patients with cutaneous melanoma less than 0.5 mm thick at diagnosis.
    Einwachter-Thompson J; MacKie RM
    Br J Dermatol; 2008 Aug; 159(2):337-41. PubMed ID: 18510665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surviving cutaneous melanoma: a clinical review of follow-up practices, surveillance, and management of recurrence.
    Mrazek AA; Chao C
    Surg Clin North Am; 2014 Oct; 94(5):989-1002, vii-viii. PubMed ID: 25245963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent malignant melanoma: the identification of prognostic factors to predict survival.
    Reintgen DS; Cox C; Slingluff CL; Seigler HF
    Ann Plast Surg; 1992 Jan; 28(1):45-9. PubMed ID: 1642405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of thick cutaneous melanoma of the trunk and extremity.
    Coit D; Sauven P; Brennan M
    Arch Surg; 1990 Mar; 125(3):322-6. PubMed ID: 2306180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early-stage non-Spitzoid cutaneous melanoma in patients younger than 22 years of age at diagnosis: long-term follow-up and survival analysis.
    Stanelle EJ; Busam KJ; Rich BS; Christison-Lagay ER; Dunkel IJ; Marghoob AA; Halpern A; Coit DG; La Quaglia MP
    J Pediatr Surg; 2015 Jun; 50(6):1019-23. PubMed ID: 25819019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up.
    Satzger I; Meier A; Hoy L; Völker B; Kapp A; Hauschild A; Gutzmer R
    Ann Surg Oncol; 2011 Feb; 18(2):514-20. PubMed ID: 20839060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
    Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
    J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
    Kurtz J; Beasley GM; Agnese D; Kendra K; Olencki TE; Terando A; Howard JH
    J Surg Res; 2017 Jun; 214():32-37. PubMed ID: 28624057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
    Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
    Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma.
    Baker JJ; Meyers MO; Frank J; Amos KD; Stitzenberg KB; Ollila DW
    Am J Surg; 2014 Apr; 207(4):549-54. PubMed ID: 24674829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience.
    Kalady MF; White RR; Johnson JL; Tyler DS; Seigler HF
    Ann Surg; 2003 Oct; 238(4):528-35; discussion 535-7. PubMed ID: 14530724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving treatment strategies in thin cutaneous head and neck melanoma: 1 institution's experience.
    Jaber JJ; Clark JI; Muzaffar K; Ruggiero FP; Feustel PJ; Frett MJ; Zender CA
    Head Neck; 2011 Jan; 33(1):7-12. PubMed ID: 20848424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is sentinel lymph node biopsy of therapeutic relevance for melanoma?
    Möhrle M; Schippert W; Rassner G; Garbe C; Breuninger H
    Dermatology; 2004; 209(1):5-13. PubMed ID: 15237261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic excision margin affects local recurrence rate: analysis of 2681 patients with melanomas < or =2 mm thick.
    McKinnon JG; Starritt EC; Scolyer RA; McCarthy WH; Thompson JF
    Ann Surg; 2005 Feb; 241(2):326-33. PubMed ID: 15650644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.